AB SCIENCE |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.952 EUR | -0.10% |
|
-7.05% | -46.61% |
| Apr. 04 | AB Science's Reconsideration Request for ALS Treatment Granted Eligibility in Canada | MT |
| Apr. 03 | AB Science: reconsideration possible for masitinib in ALS | CF |
| Sales 2023 * | 930K 994K | Sales 2024 * | 990K 1.06M | Capitalization | 101M 108M |
|---|---|---|---|---|---|
| Net income 2023 * | -19M -20.31M | Net income 2024 * | -18M -19.24M | EV / Sales 2023 * | 109 x |
| Net cash position 2023 * | - 0 | Net cash position 2024 * | - 0 | EV / Sales 2024 * | 102 x |
| P/E ratio 2023 * |
-5.21
x | P/E ratio 2024 * |
-5.5
x | Employees | 89 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 66.05% |
More Fundamentals
* Assessed data
More news
Latest transcript on AB Science
More press releases
More news
| 1 day | -0.15% | ||
| 1 week | -7.05% | ||
| Current month | -23.55% | ||
| 1 month | -23.10% | ||
| 3 months | -46.76% | ||
| 6 months | -16.29% | ||
| Current year | -46.61% |
1 week
1.91
1.98
1 month
1.912.56
Current year
1.913.71
1 year
1.916.36
3 years
1.9116.30
5 years
1.9120.10
10 years
1.9120.10
| Managers | Title | Age | Since |
|---|---|---|---|
Alain Moussy
CEO | Chief Executive Officer | - | 01-07-10 |
Laurent Guy
DFI | Director of Finance/CFO | - | 01-12-31 |
| Chief Tech/Sci/R&D Officer | - | 18-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Alain Moussy
CEO | Chief Executive Officer | - | 01-07-10 |
Patrick Moussy
BRD | Director/Board Member | - | 01-07-10 |
| Director/Board Member | 62 | 21-06-26 |
| Date | Price | Change |
|---|---|---|
| 24-04-24 | 1.938 | -0.82% |
| 24-04-23 | 1.954 | +1.35% |
| 24-04-22 | 1.928 | +0.94% |
| 24-04-19 | 1.91 | -3.73% |
| 24-04-18 | 1.984 | -4.84% |
Delayed Quote Deutsche Boerse AG, April 24, 2024 at 02:04 am EDT
More quotes
AB Science specializes in research, development, and sales of kinase protein inhibitors (KPI), therapeutic drugs used in treating cancerous tumors, inflammatory and neuro-degenerative diseases in both humans and animals.
Sector
Pharmaceuticals
Calendar
2024-04-29
- Q4 2023 Earnings Release
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.98
EUR
Average target price
6.895
EUR
Spread / Average Target
+248.23%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +11.94% | 9.18B | |
| -16.33% | 4.79B | |
| +6.40% | 3.97B | |
| +26.98% | 3.98B | |
| +27.42% | 2.56B | |
| -26.55% | 2.29B | |
| -25.02% | 2.23B | |
| +5.82% | 1.92B | |
| -0.50% | 1.64B |
- Stock Market
- Equities
- AB Stock
- A8D Stock
